Earnings Feed
Start Free
Home/Filings/4/0001209191-23-047429
4//SEC Filing

Yang Xiaodong 4

Accession 0001209191-23-047429

CIK 0001814140other
View on SEC.govCompany Profile

Filed

Aug 24, 8:00 PM ET

Accepted

Aug 25, 6:37 PM ET

Size

39.1 KB

Accession

0001209191-23-047429

Insider Transaction Report

Form 4
Period: 2023-08-23
Apexigen, Inc.APGN
Yang Xiaodong
DirectorChief Executive Officer
Transactions
  • Award

    Common Stock

    2023-08-23+400,000→ 932,890 total
  • Disposition to Issuer

    Common Stock

    2023-08-23−863,729→ 0 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−30,734→ 0 total
    Exercise: $2.25Exp: 2027-02-17→ Common Stock (30,734 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−99,373→ 0 total
    Exercise: $6.54Exp: 2029-02-14→ Common Stock (99,373 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−12,296→ 0 total
    Exercise: $7.03Exp: 2030-02-20→ Common Stock (12,296 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−305,000→ 0 total
    Exercise: $2.46Exp: 2032-10-07→ Common Stock (305,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−461,015→ 0 total
    Exercise: $1.66Exp: 2025-10-30→ Common Stock (461,015 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−295,978→ 0 total
    Exercise: $3.62Exp: 2028-05-22→ Common Stock (295,978 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−20,489→ 0 total
    Exercise: $1.47Exp: 2025-06-25→ Common Stock (20,489 underlying)
  • Tax Payment

    Common Stock

    2023-08-23$0.39/sh−69,161$26,634→ 863,729 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−219,950→ 0 total
    Exercise: $1.27Exp: 2023-10-29→ Common Stock (219,950 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−35,856→ 0 total
    Exercise: $2.25Exp: 2026-12-16→ Common Stock (35,856 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−38,417→ 0 total
    Exercise: $4.59Exp: 2031-02-12→ Common Stock (38,417 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-08-23−79,906→ 0 total
    Exercise: $4.59Exp: 2030-02-20→ Common Stock (79,906 underlying)
  • Disposition to Issuer

    Warrant (right to buy)

    2023-08-23−10,000→ 0 total
    Exercise: $11.50Exp: 2027-07-29→ Common Stock (10,000 underlying)
Footnotes (16)
  • [F1]The reported shares are represented by restricted stock units, or RSUs, awarded upon the achievement of certain performance metrics of which 200,000 RSUs vested at the Effective Time as defined below and the remaining RSUs vest in two equal six month installments beginning on February 23, 2024.
  • [F10]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 51,055 shares of Pyxis common stock at an exercise price of $20.99 per share.
  • [F11]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,141 shares of Pyxis common stock at an exercise price of $37.92 per share.
  • [F12]The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 2,120 shares of Pyxis common stock at an exercise price of $40.76 per share.
  • [F13]The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 13,783 shares of Pyxis common stock at an exercise price of $26.61 per share.
  • [F14]The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2021. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 6,626 shares of Pyxis common stock at an exercise price of $26.61 per share.
  • [F15]The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2022. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 52,612 shares of Pyxis common stock at an exercise price of $14.27 per share.
  • [F16]The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 1,725 shares of Pyxis common stock at an exercise price of $66.67 per share.
  • [F2]The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.
  • [F3]This amount includes 200,000 shares represented by RSUs.
  • [F4]Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share and each outstanding RSU was assumed by Pyxis and converted into a restricted stock unit for 34,500 shares of Pyxis common stock.
  • [F5]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 37,940 shares of Pyxis common stock at an exercise price of $7.37 per share.
  • [F6]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,533 shares of Pyxis common stock at an exercise price of $8.53 per share.
  • [F7]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 79,524 shares of Pyxis common stock at an exercise price of $9.63 per share.
  • [F8]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 6,184 shares of Pyxis common stock at an exercise price of $13.05 per share.
  • [F9]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 5,300 shares of Pyxis common stock at an exercise price of $13.05 per share.

Documents

1 file

Issuer

Apexigen, Inc.

CIK 0001814140

→
Entity typeother

Related Parties

1
  • filerCIK 0001940817

Filing Metadata

Form type
4
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 6:37 PM ET
Size
39.1 KB
View on SEC.gov